Literature DB >> 27872087

Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma.

Clémence Granier1, Charles Dariane1,2, Pierre Combe1,3, Virginie Verkarre4, Saïk Urien5,6, Cécile Badoual1,4, Hélène Roussel1,4, Marion Mandavit1, Patrice Ravel7, Mathilde Sibony8, Lucie Biard9, Camélia Radulescu10, Emeline Vinatier1,11, Nadine Benhamouda1,11, Michael Peyromaure12, Stéphane Oudard1,3, Arnaud Méjean2, Marc-Olivier Timsit2, Alain Gey1,11, Eric Tartour13,11.   

Abstract

Inhibitory receptors expressed by T cells mediate tolerance to tumor antigens, with coexpression of these receptors exacerbating this dysfunctional state. Using the VectraR automated multiparametric immunofluorescence technique, we quantified intratumoral CD8+ T cells coexpressing the inhibitory receptors PD-1 and Tim-3 from patients with renal cell carcinoma (RCC). A second validation cohort measured the same parameters by cytometry. The percentage of tumor-infiltrating CD8+ T cells coexpressing PD-1 and Tim-3 correlated with an aggressive phenotype and a larger tumor size at diagnosis. Coexpression of PD-1 and Tim-3 above the median conferred a higher risk of relapse and a poorer 36-month overall survival. Notably, other CD8+T-cell subsets did not exert a similar effect on overall survival. Moreover, only the PD-1+Tim-3+ subset of CD8+ T cells exhibited impaired function after stimulation. Our findings establish intratumoral Tim-3+PD1+CD8+ T cells as critical mediators of an aggressive phenotype in RCC. Use of the Vectra tool may be useful to identify similarly critical prognostic and predictive biomarkers in other tumor types and their response to immunotherapy. Cancer Res; 77(5); 1075-82. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27872087     DOI: 10.1158/0008-5472.CAN-16-0274

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  58 in total

1.  Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade.

Authors:  Mikaël Roussel; Kieu-Suong Le; Clémence Granier; Francisco Llamas Gutierrez; Etienne Foucher; Simon Le Gallou; Céline Pangault; Luc Xerri; Vincent Launay; Thierry Lamy; Eric Tartour; Daniel Olive; Thierry Fest
Journal:  Blood Adv       Date:  2021-04-13

2.  irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.

Authors:  Jean-Christophe Pignon; Opeyemi Jegede; Sachet A Shukla; David A Braun; Christine E Horak; Megan Wind-Rotolo; Yuko Ishii; Paul J Catalano; Jonian Grosha; Abdallah Flaifel; Jesse S Novak; Kathleen M Mahoney; Gordon J Freeman; Arlene H Sharpe; F Stephen Hodi; Robert J Motzer; Toni K Choueiri; Catherine J Wu; Michael B Atkins; David F McDermott; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2019-01-22       Impact factor: 12.531

3.  The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis.

Authors:  Julie Ahn; Justin A Bishop; Richard B S Roden; Clint T Allen; Simon R A Best
Journal:  Laryngoscope       Date:  2017-09-22       Impact factor: 3.325

Review 4.  Targeting novel inhibitory receptors in cancer immunotherapy.

Authors:  Quan-Quan Ding; Joe-Marc Chauvin; Hassane M Zarour
Journal:  Semin Immunol       Date:  2020-12-04       Impact factor: 11.130

5.  Tim-3 exacerbates kidney ischaemia/reperfusion injury through the TLR-4/NF-κB signalling pathway and an NLR-C4 inflammasome activation.

Authors:  Y Guo; J Zhang; X Lai; M Chen; Y Guo
Journal:  Clin Exp Immunol       Date:  2018-05-07       Impact factor: 4.330

Review 6.  Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints.

Authors:  Kristian M Hargadon
Journal:  Clin Transl Med       Date:  2020-01

7.  Tim3+ Foxp3 + Treg Cells Are Potent Inhibitors of Effector T Cells and Are Suppressed in Rheumatoid Arthritis.

Authors:  Huaqiang Sun; Wenwu Gao; Wenping Pan; Qian Zhang; Gongteng Wang; Dapeng Feng; Xiubin Geng; Xinfeng Yan; Shufeng Li
Journal:  Inflammation       Date:  2017-08       Impact factor: 4.092

8.  Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells.

Authors:  Clémence Granier; Emeline Vinatier; Elia Colin; Marion Mandavit; Charles Dariane; Virginie Verkarre; Lucie Biard; Rami El Zein; Corinne Lesaffre; Isabelle Galy-Fauroux; Hélène Roussel; Eléonore De Guillebon; Charlotte Blanc; Antonin Saldmann; Cécile Badoual; Alain Gey; Éric Tartour
Journal:  J Vis Exp       Date:  2018-02-08       Impact factor: 1.355

Review 9.  Prognostic impact of PD-1 and its ligands in renal cell carcinoma.

Authors:  Franziska Erlmeier; Wilko Weichert; Andres Jan Schrader; Michael Autenrieth; Arndt Hartmann; Sandra Steffens; Philipp Ivanyi
Journal:  Med Oncol       Date:  2017-04-21       Impact factor: 3.064

Review 10.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.

Authors:  Daniela Bruni; Helen K Angell; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2020-08-04       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.